This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brandtzaeg, P. Articles by Kierulf, P. Search for Related Content PubMed PubMed Citation Articles by Brandtzaeg, P. Articles by Kierulf, P. Social Bookmarking                         What's this?

Invited review: Neisseria meningitidis lipopolysaccharides in human pathology

Department of Pediatrics, UllevÅl University Hospital, University of Oslo, Oslo, Norway, petter.brandtzag{at}ioks.uio.no

Anna Bjerre

Department of Pediatrics, UllevÅl University Hospital, University of Oslo, Oslo, Norway, Department of Clinical Chemistry, UllevÅl University Hospital, University of Oslo, Oslo, Norway

Reidun Øvstebø

Department of Clinical Chemistry, UllevÅl University Hospital, University of Oslo, Oslo, Norway

Berit Brusletto

Department of Clinical Chemistry, UllevÅl University Hospital, University of Oslo, Oslo, Norway

Gun Britt Joø

Department of Clinical Chemistry, UllevÅl University Hospital, University of Oslo, Oslo, Norway

Peter Kierulf

Department of Clinical Chemistry, UllevÅl University Hospital, University of Oslo, Oslo, Norway

Neisseria meningitidis causes meningitis, fulminant septicemia or mild meningococcemia attacking mainly children and young adults. Lipopolysaccharides (LPS) consist of a symmetrical hexa-acyl lipid A and a short oligosaccharide chain and are classified in 11 immunotypes. Lipid A is the primary toxic component of N. meningitidis . LPS levels in plasma and cerebrospinal fluid as determined by Limulus amebocyte lysate (LAL) assay are quantitatively closely associated with inflammatory mediators, clinical symptoms, and outcome. Patients with persistent septic shock, multiple organ failure, and severe coagulopathy reveal extraordinarily high levels of LPS in plasma. The cytokine production is compartmentalized to either the circulation or to the subarachnoid space. Mortality related to shock increases from 0% to > 80% with a 10-fold increase of plasma LPS from 10 to 100 endotoxin units/ml. Hemorrhagic skin lesions and thrombosis are caused by up-regulation of tissue factor which induces coagulation, and by inhibition of fibrinolysis by plasminogen activator inhibitor 1 (PAI-1). Effective antibiotic treatment results in a rapid decline of plasma LPS (half-life 1—3 h) and cytokines, and reduced generation of thrombin, and PAI-1. Early antibiotic treatment is mandatory. Three intervention trials to block lipid A have not significantly reduced the mortality of meningococcal septicemia.

Journal of Endotoxin Research, Vol. 7, No. 6, 401-420 (2001)
DOI: 10.1177/09680519010070060401


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?